Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 7/20 | 0.72 |
| ▸ | CA1 | P00915 | 1/20 | 0.71 |
| ▸ | CES2 | O00748 | 4/20 | 0.67 |
| ▸ | CES1 | P23141 | 4/20 | 0.67 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Undecanoate SCHEMBL8373641 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Octanoic Acid SCHEMBL296588 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Stearic Acid SCHEMBL3529907 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Myristic Acid SCHEMBL628568 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Stearic Acid SCHEMBL4099 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| SCHEMBL5963308 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Palmitic Acid SCHEMBL138023 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Decanoic Acid SCHEMBL517894 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Dodecanoate SCHEMBL114206 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Pentadecanoic Acid SCHEMBL18429970 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583208-B2 | Multilayer structure, packaging material in which same is utilized, regrind composition, and method for producing regrind composition | KURARAY CO., LTD. (JP) | 2026-03-24 | — | — | US | disclosed |
| US-20240269969-A1 | MULTILAYER STRUCTURE, PACKAGING MATERIAL IN WHICH SAME IS UTILIZED, REGRIND COMPOSITION, AND METHOD FOR PRODUCING REGRIND COMPOSITION | KURARAY CO., LTD. (JP) | 2024-08-15 | — | — | US | disclosed |
| CN-118056792-A | Method and system for removing fluoride ions in mine water by utilizing coal mine underground reservoir rock | 国能神东煤炭集团有限责任公司 | 2024-05-21 | — | — | CN | disclosed |
| CN-116096650-A | Multilayer structure, packaging material using same, recovery composition, and method for producing recovery composition | 株式会社可乐丽 | 2023-05-09 | — | — | CN | disclosed |
| EP-0624553-B1 | Process for producing photochromic titanium oxide compounds | SUMITOMO CHEMICAL CO (JP) | 1999-08-04 | — | — | EP | disclosed |
| EP-0624553-A1 | Process for producing photochromic titanium oxide compounds | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1994-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583208-B2 | Multilayer structure, packaging material in which same is utilized, regrind composition, and method for producing regrind composition | CD68, MRE11, MLEC | FABP3 1572/4885CA1 38/4885CES2 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.